Identification
- Summary
Leuprolide is a peptide-based GnRH receptor superagonist used for the palliative treatment of prostate cancer, uterine leiomyomata, endometriosis, and central precocious puberty.
- Brand Names
- Camcevi, Eligard, Fensolvi, Lupaneta Pack 1-month, Lupron, Lupron Depot-ped, Viadur, Zeulide Depot
- Generic Name
- Leuprolide
- DrugBank Accession Number
- DB00007
- Background
Leuprolide is a synthetic 9-residue peptide analogue of gonadotropin-releasing hormone (GnRH). Unlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three hours.4 As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels. Prolonged activation of GnRHR results in significant downregulation of sex steroid levels, which is primarily responsible for the clinical efficacy of leuprolide in diverse conditions, including advanced prostate cancer, endometriosis, and central precocious puberty.1,3
Leuprolide was first approved in 1985 as a daily subcutaneous injection under the tradename Lupron™ by Abbvie Endocrine Inc.11 Since this initial approval, various long-acting intramuscular and subcutaneous products have been developed such that patients can be dosed once every six months.6,9 Leuprolide remains frontline therapy in all conditions for which it is indicated for use.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Leuprolide (DB00007)
- Weight
- Average: 1209.3983
Monoisotopic: 1208.645462232 - Chemical Formula
- C59H84N16O12
- Synonyms
- Leuprorelin
- Leuprorelina
- Leuproreline
- Leuprorelinum
- External IDs
- CKD-841
Pharmacology
- Indication
Leuprolide is indicated for the treatment of advanced prostate cancer 6,12 and as palliative treatment of advanced prostate cancer.9
It is also used for the treatment of pediatric patients with central precocious puberty (CPP).7,8
In combination with oral norethisterone (also known as norethindrone), leuprolide is also indicated for the initial treatment of the symptoms of endometriosis.5 Finally, in combination with iron supplementation, leuprolide is indicated for the preoperative hematological improvement of anemic patients with uterine leiomyomata (uterine fibroids).10
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Treatment of Advanced prostate cancer •••••••••••• Treatment of Advanced prostate cancer •••••••••••• Treatment of Advanced prostate cancer •••••••••••• Treatment of Advanced prostate cancer •••••••••••• Treatment of Advanced prostate cancer •••••••••••• ••••• - Associated Therapies
- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Leuprolide is a gonadotropin-releasing hormone (GnRH) analogue that functions as a GnRH receptor superagonist.3,4 After an initial spike in GnRH-mediated steroidal production, including testosterone and estradiol, prolonged use results in a significant drop in circulating steroid levels, in line with those produced through other forms of androgen-deprivation therapy (ADT).1,2,3 The corresponding hormonal/steroidal changes produce specific adverse effects in different patient populations.
In women undergoing treatment for endometriosis or uterine leiomyomata, careful consideration regarding pregnancy status is advised. The initial increase in estradiol levels may worsen symptoms such as pain and bleeding. Long-term use of leuprolide is associated with loss of bone mineral density. Patients co-administered with norethisterone may experience sudden vision loss, proptosis, diplopia, migraine, thrombophlebitis, and pulmonary embolism and may also be at higher risk of cardiovascular disease. Patients with a history of depression may experience severe recurrence of depressive symptoms.5,10
In men undergoing palliative treatment for advanced/metastatic prostate cancer, short-term spikes in testosterone levels may cause tumour flare and associated symptoms such as bone pain, hematuria, neuropathy, bladder and/or ureteral obstruction, and spinal cord compression. In addition, patients are at increased risk of developing hyperglycemia, diabetes, and cardiovascular disease, which may manifest through myocardial infarction, stroke, cardiac death, or prolonged QT/QTc interval. In addition, Leuprolide may cause convulsions and embryo-fetal toxicity.6,9
In pediatric patients undergoing treatment for central precocious puberty (CPP), the initial steroidal spike may be associated with increased clinical signs of puberty within 2-4 weeks of treatment initiation. In addition, leuprolide may cause convulsions and psychiatric symptoms, including irritability, impatience, aggression, anger, and crying.7,8
- Mechanism of action
Gonadotropin-releasing hormone (GnRH) is a naturally occurring decapeptide that modulates the hypothalamic-pituitary-gonadal (HPG) axis. GnRH binds to corresponding receptors (GnRHRs) on the anterior pituitary gonadotropes, which in turn release luteinizing hormone (LH) and follicle-stimulating hormone (FSH); these, in turn, affect the downstream synthesis and release of the sex hormones testosterone, dihydrotestosterone, estrone, and estradiol.1,3
Despite the variety of conditions indicated for treatment with leuprolide, the mechanism of action underlying efficacy is the same in all cases. As a GnRHR agonist, leuprolide binds to and initially activates downstream LH and FSH release; this initial spike in gonadotropin levels is responsible for some of the adverse effects associated with treatment. After 2-4 weeks of treatment, continuous stimulation of GnRHR results in feedback inhibition and significant downregulation of LH, FSH, and their corresponding downstream effects, producing a therapeutic benefit. These effects are reversible upon treatment discontinuation.1,2,3,4,5,6,7,8,9,10
Target Actions Organism AGonadotropin-releasing hormone receptor agonistHumans - Absorption
Leuprolide is typically administered as a single-dose long-acting formulation employing either microsphere or biodegradable solid depot technologies.1 Regardless of the exact formulation and initial dose strength, the Cmax is typically achieved by 4-5 hours post-injection and displays large variability in the range of 4.6 - 212 ng/mL. Eventual steady-state kinetics are typically achieved by four weeks, with a narrower range of 0.1 - 2 ng/mL. No studies on the effects of food on absorption have been carried out.5,6,7,8,9,10,12
- Volume of distribution
Leuprolide has an apparent steady-state volume of distribution of 27 L following intravenous bolus administration to healthy males. The volume of distribution for indicated routes of subcutaneous or intramuscular injection has not been reported.5,6,7,8,9,10,12
- Protein binding
Leuprolide displays in vitro binding to human plasma proteins between 43% and 49%.5,6,7,8,9,10,12
- Metabolism
Radiolabeling studies suggest that leuprolide is primarily metabolized to inactive penta-, tri-, and dipeptide entities, which are likely further metabolized. It is expected that various peptidases encountered throughout systemic circulation are responsible for leuprolide metabolism.5,6,7,8,9,10,12
- Route of elimination
Following administration of 3.75 mg leuprolide depot suspension to three patients, less than 5% of the initial dose was recovered as unchanged or pentapeptide metabolite in the urine.5,6,7,10
- Half-life
Leuprolide has a terminal elimination half-life of approximately three hours.5,6,7,8,9,10,12
- Clearance
Leuprolide administered as a 1 mg intravenous bolus in healthy males has a mean systemic clearance between 7.6 and 8.3 L/h.5,6,7,8,9,10,12
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Leuprolide is considered extremely safe, with low dose-related toxicity and comparatively mild adverse effects.1 Prostate cancer patients treated with leuprolide at doses as high as 20 mg/day for two years showed no additional adverse effects compared to those receiving 1 mg/day.10
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Leuprolide may decrease the excretion rate of Abacavir which could result in a higher serum level. Acarbose The therapeutic efficacy of Acarbose can be decreased when used in combination with Leuprolide. Aceclofenac Aceclofenac may decrease the excretion rate of Leuprolide which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Leuprolide which could result in a higher serum level. Acetaminophen Leuprolide may decrease the excretion rate of Acetaminophen which could result in a higher serum level. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Leuprolide acetate 37JNS02E7V 74381-53-6 YFDMUNOZURYOCP-XNHQSDQCSA-N Leuprolide mesylate 8E3C3C493W 944347-41-5 MBIDSOMXPLCOHS-XNHQSDQCSA-N - International/Other Brands
- Camcevi (Foresee Pharmaceuticals) / Leuplin (Takeda) / LeuProMaxx (Baxter/Teva) / Memryte (Curaxis) / Prostap 3 (Takeda UK) / Prostap SR (Takeda UK)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Camcevi Injection, emulsion 42 mg/1mL Subcutaneous Foresee Pharmaceuticals Co., Ltd. 2022-12-30 Not applicable US 
Camcevi 42 mg / syr Subcutaneous Accord Healthcare Inc Not applicable Not applicable Canada 
Camcevi 42 mg Subcutaneous Accord Healthcare S.L.U. 2022-06-21 Not applicable EU 
Camcevi Injection, emulsion 42 mg/0.37g Subcutaneous Accord BioPharma, Inc. 2022-04-05 Not applicable US Eligard Injection, suspension, extended release 30 mg/0.5mL Subcutaneous TOLMAR Inc. 2024-01-11 Not applicable US - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Leuprolide Acetate Injection, solution 1 mg/.2mL Subcutaneous Eon Labs, Inc. 1998-08-04 Not applicable US Leuprolide Acetate Kit 1 mg/0.2mL Subcutaneous; Topical Teva Parenteral Medicines, Inc. 2000-11-06 2011-03-31 US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Leuprolide Acetate Leuprolide acetate (5 mg/1mL) + Isopropyl alcohol (0.7 mL/1mL) Injection, solution; Kit; Swab Subcutaneous; Topical Northstar RxLLC 2022-08-01 Not applicable US Leuprolide Acetate Leuprolide acetate (1 mg/0.2mL) + Isopropyl alcohol (1 mL/1mL) Injection, solution; Kit Subcutaneous; Topical VGYAAN Pharmaceuticals LLC 2020-10-25 Not applicable US Leuprolide Acetate Leuprolide acetate + Isopropyl alcohol Kit Subcutaneous; Topical Genzyme Corporation 2006-05-31 2006-05-31 US Leuprolide Acetate Leuprolide acetate (1 mg/0.2mL) + Isopropyl alcohol (0.7 mL/1mL) Kit Subcutaneous; Topical Sandoz Inc 1998-08-04 Not applicable US Leuprolide Acetate Leuprolide acetate (5 mg/1mL) + Isopropyl alcohol (0.7 mL/1mL) Injection, solution; Kit Subcutaneous; Topical Northstar RxLLC 2023-03-01 Not applicable US
Categories
- ATC Codes
- L02AE51 — Leuprorelin and bicalutamide
- L02AE — Gonadotropin releasing hormone analogues
- L02A — HORMONES AND RELATED AGENTS
- L02 — ENDOCRINE THERAPY
- L — ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
- Drug Categories
- Adrenal Cortex Hormones
- Agents Causing Muscle Toxicity
- Amino Acids, Peptides, and Proteins
- Antineoplastic Agents
- Antineoplastic Agents, Hormonal
- Antineoplastic and Immunomodulating Agents
- Drugs causing inadvertant photosensitivity
- Drugs that are Mainly Renally Excreted
- Endocrine Therapy
- Fertility Agents
- Fertility Agents, Female
- Gonadotropin Releasing Hormone Receptor Agonist
- Gonadotropin Releasing Hormone Receptor Agonists
- Gonadotropin-releasing hormone agonist
- Gonadotropins
- Hormones and Related Agents
- Hyperglycemia-Associated Agents
- Hypothalamic Hormones
- Moderate Risk QTc-Prolonging Agents
- Nerve Tissue Proteins
- Neuropeptides
- Oligopeptides
- Peptides
- Photosensitizing Agents
- Pituitary Hormone-Releasing Hormones
- Proteins
- QTc Prolonging Agents
- Reproductive Control Agents
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- EFY6W0M8TG
- CAS number
- 53714-56-0
- InChI Key
- GFIJNRVAKGFPGQ-LIJARHBVSA-N
- InChI
- InChI=1S/C59H84N16O12/c1-6-63-57(86)48-14-10-22-75(48)58(87)41(13-9-21-64-59(60)61)68-51(80)42(23-32(2)3)69-52(81)43(24-33(4)5)70-53(82)44(25-34-15-17-37(77)18-16-34)71-56(85)47(30-76)74-54(83)45(26-35-28-65-39-12-8-7-11-38(35)39)72-55(84)46(27-36-29-62-31-66-36)73-50(79)40-19-20-49(78)67-40/h7-8,11-12,15-18,28-29,31-33,40-48,65,76-77H,6,9-10,13-14,19-27,30H2,1-5H3,(H,62,66)(H,63,86)(H,67,78)(H,68,80)(H,69,81)(H,70,82)(H,71,85)(H,72,84)(H,73,79)(H,74,83)(H4,60,61,64)/t40-,41-,42-,43+,44-,45-,46-,47-,48-/m0/s1
- IUPAC Name
- (2S)-1-[(2S)-5-carbamimidamido-2-[(2S)-2-[(2R)-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-2-[(2S)-3-(1H-imidazol-4-yl)-2-{[(2S)-5-oxopyrrolidin-2-yl]formamido}propanamido]-3-(1H-indol-3-yl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-4-methylpentanamido]-4-methylpentanamido]pentanoyl]-N-ethylpyrrolidine-2-carboxamide
- SMILES
- CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CO)NC(=O)[C@H](CC1=CNC2=C1C=CC=C2)NC(=O)[C@H](CC1=CNC=N1)NC(=O)[C@@H]1CCC(=O)N1
References
- Synthesis Reference
Daniel Kadzimirzs, Gerhard Jas, Volker Autze, "Solution-Phase Synthesis of Leuprolide and Its Intermediates." U.S. Patent US20090005535, issued January 01, 2009.
US20090005535- General References
- Hoda MR, Kramer MW, Merseburger AS, Cronauer MV: Androgen deprivation therapy with Leuprolide acetate for treatment of advanced prostate cancer. Expert Opin Pharmacother. 2017 Jan;18(1):105-113. doi: 10.1080/14656566.2016.1258058. Epub 2016 Nov 28. [Article]
- Ali M, Chaudhry ZT, Al-Hendy A: Successes and failures of uterine leiomyoma drug discovery. Expert Opin Drug Discov. 2018 Feb;13(2):169-177. doi: 10.1080/17460441.2018.1417381. Epub 2017 Dec 18. [Article]
- Wilson AC, Meethal SV, Bowen RL, Atwood CS: Leuprolide acetate: a drug of diverse clinical applications. Expert Opin Investig Drugs. 2007 Nov;16(11):1851-63. doi: 10.1517/13543784.16.11.1851. [Article]
- Conn PM, Crowley WF Jr: Gonadotropin-releasing hormone and its analogues. N Engl J Med. 1991 Jan 10;324(2):93-103. doi: 10.1056/NEJM199101103240205. [Article]
- FDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use [Link]
- FDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension, for intramuscular injection [Link]
- FDA Approved Drug Products: Lupron Depot-Ped (leuprolide acetate) depot suspension [Link]
- FDA Approved Drug Products: Fensolvi (leuprolide acetate) suspension [Link]
- FDA Approved Drug Products: ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use [Link]
- FDA Approved Drug Products: Lupron Depot 3.75mg (leuprolide acetate) depot suspension [Link]
- FDA Approved Drug Products: Lupron (leuprolide) injection; discontinued [Link]
- FDA Approved Drug Products: CAMCEVI (leuprolide) injectable emulsion, for subcutaneous use [Link]
- FDA Approved Drug Products: LUPRON DEPOT (leuprolide acetate for depot suspension) (Dec 2023) [Link]
- External Links
- Human Metabolome Database
- HMDB0041916
- KEGG Drug
- D08113
- KEGG Compound
- C07612
- PubChem Substance
- 46507635
- ChemSpider
- 571356
- BindingDB
- 50369395
- 42375
- ChEBI
- 6427
- ChEMBL
- CHEMBL1201199
- Therapeutic Targets Database
- DAP000020
- PharmGKB
- PA450203
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Leuprorelin
- FDA label
- Download (477 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Effect of Two Protocols of Ovarian Stimulation on Oocyte Quality 1 4 Completed Not Available Endometriosis 1 4 Completed Not Available Prostate Cancer 1 4 Completed Basic Science Contraception / Fertility 1 4 Completed Basic Science Depression / Hot Flashes / Menopause 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Abbott Laboratories Ltd.
- Cardinal Health
- Eon Labs
- Hospira Inc.
- Oso Biopharmaceuticals Manufacturing LLC
- Physicians Total Care Inc.
- Sanofi-Aventis Inc.
- Sun Pharmaceutical Industries Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Teva Pharmaceutical Industries Ltd.
- Tolmar Inc.
- Dosage Forms
Form Route Strength Injection, emulsion Subcutaneous 42 mg/1mL Injection, emulsion Subcutaneous 42 mg/0.37g Injection, suspension Subcutaneous 42 mg Injection, powder, for solution Parenteral 22.5 MG Injection, powder, for solution Parenteral 45 MG Injection, powder, for solution Parenteral 7.5 MG Injection, powder, for solution Subcutaneous Injection, powder, for suspension, extended release Subcutaneous 22.5 mg / syr Injection, powder, for suspension, extended release Subcutaneous 30 mg / syr Injection, powder, for suspension, extended release Subcutaneous 45 mg / syr Injection, powder, for suspension, extended release Subcutaneous 7.5 mg / syr Injection, suspension, extended release Subcutaneous 22.5 mg/0.375mL Injection, suspension, extended release Subcutaneous 30 mg/0.5mL Injection, suspension, extended release Subcutaneous 45 mg/0.375mL Injection, suspension, extended release Subcutaneous 7.5 mg/0.25mL Kit Subcutaneous 22.5 mg/0.375mL Kit Subcutaneous 30 mg/0.5mL Kit Subcutaneous 45 mg/0.375mL Kit Subcutaneous 7.5 mg/0.25mL Suspension Subcutaneous 7.500 mg Injection, powder, lyophilized, for suspension, extended release Subcutaneous 22.5 mg Injection, powder, lyophilized, for suspension, extended release Subcutaneous 45 mg Injection, powder, lyophilized, for suspension, extended release Subcutaneous 7.5 mg Injection, powder, for suspension Subcutaneous 45 mg Injection, powder, for suspension Subcutaneous 4500000 mg Powder Intramuscular 22.5 mg/1vial Injection Intramuscular 22.5 mg Injection, powder, for solution Subcutaneous 22.5 MG Powder Intramuscular 45 mg/1vial Injection, solution Intramuscular 45 mg Injection, solution Subcutaneous 45 mg Injection, powder, for solution Subcutaneous 45 MG Injection, solution Intramuscular Injection, solution Subcutaneous 7.5 mg Powder Intramuscular 7.5 mg/1vial Injection, powder, for solution Subcutaneous 7.5 mg Injection, powder, for solution Parenteral Injection, powder, for suspension Subcutaneous 22.5 mg Injection, powder, lyophilized, for solution Subcutaneous 22.5 mg Injection, powder, for suspension Subcutaneous 7.5 mg Injection, powder, lyophilized, for solution Subcutaneous 7.5 mg Injection, powder, for suspension Parenteral 7.5 mg Injection Intramuscular 3.75 MG Injection, powder, for suspension Intramuscular; Subcutaneous 11.25 MG/ML Injection, powder, for suspension Intramuscular; Subcutaneous 3.75 MG/ML Injection, powder, for suspension, extended release Intramuscular 11.25 MG/2ML Injection, powder, for suspension, extended release Intramuscular 3.75 MG/2ML Injection, solution Subcutaneous 1 MG/0.2ML Powder Intramuscular 11.25 mg/1vial Injection, powder, for suspension Subcutaneous 3.75 mg Injection, suspension, extended release; kit Subcutaneous 45 mg/0.375mL Injection, powder, for suspension Intramuscular 11.25 mg Injection, powder, for suspension Intramuscular 3.75 mg Powder Intramuscular 22.5 mg Powder Intramuscular 7.5 mg Implant Parenteral 3.6 MG Implant Parenteral 5 MG Implant Subcutaneous 3.6 MG Implant Subcutaneous 5 MG Injection, solution Subcutaneous 1 mg/.2mL Injection, solution; kit Subcutaneous; Topical Injection, solution; kit; swab Subcutaneous; Topical Kit Subcutaneous Kit Subcutaneous; Topical 1 mg/0.2mL Injection, powder, lyophilized, for suspension, extended release; kit Intramuscular 22.5 mg/2mL Liquid Subcutaneous 5 mg / mL Implant Parenteral Implant Subcutaneous Suspension Parenteral 3.75 mg Solution Parenteral 5 mg Suspension Intramuscular Injection, solution Subcutaneous 5 mg/ml Suspension Intramuscular 11.250 mg Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 3.75 mg Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous 11.25 mg Injection Intramuscular Injection, powder, for solution Intramuscular; Subcutaneous 11.25 mg Injection, powder, for solution Intramuscular; Subcutaneous 3.75 mg Injection Subcutaneous Injection, powder, for solution Subcutaneous 30 mg Injection, powder, lyophilized, for solution Intramuscular; Subcutaneous Injection Subcutaneous 5 mg/ml Injection, powder, lyophilized, for suspension; kit; tablet Intramuscular; Oral; Topical Kit Subcutaneous; Topical 5 mg/1mL Solution Subcutaneous 5 mg / mL Solution Subcutaneous 5 mg Injection, powder, for suspension, extended release Intramuscular 11.25 mg / syr Injection, powder, for suspension, extended release Intramuscular 11.25 mg / vial Injection, powder, for suspension, extended release Intramuscular 15 mg / vial Injection, powder, for suspension, extended release Intramuscular 22.5 mg / syr Injection, powder, for suspension, extended release Intramuscular 3.75 mg / syr Injection, powder, for suspension, extended release Intramuscular 30 mg / syr Injection, powder, for suspension, extended release Intramuscular 7.5 mg / syr Injection, powder, lyophilized, for suspension Intramuscular 3.75 mg/1mL Injection, powder, lyophilized, for suspension Intramuscular 30 mg/1.5mL Injection, powder, lyophilized, for suspension; kit Intramuscular 22.5 mg/1.5mL Injection, powder, lyophilized, for suspension; kit Intramuscular 30 mg/1.5mL Injection, powder, lyophilized, for suspension; kit Intramuscular 45 mg/1.5mL Injection, powder, lyophilized, for suspension; kit Intramuscular 7.5 mg/1mL Injection, powder, lyophilized, for suspension; kit Intramuscular; Topical Kit Intramuscular; Topical 3.75 mg/1mL Injection, powder, for suspension Intramuscular; Subcutaneous 11.25 mg Injection, powder, lyophilized, for suspension Intramuscular 11.25 mg/1mL Injection, powder, lyophilized, for suspension Intramuscular 15 mg/1mL Injection, powder, lyophilized, for suspension Intramuscular 7.5 mg/1mL Injection, powder, lyophilized, for suspension; kit Intramuscular 11.25 mg/1.5mL Injection, powder, lyophilized, for suspension; kit Intramuscular 11.25 mg/1mL Injection, powder, lyophilized, for suspension; kit Intramuscular 15 mg/1mL Kit Intramuscular; Topical 11.25 mg/1mL Injection, powder, for suspension Intramuscular; Subcutaneous 30 mg Injection, powder, for suspension Parenteral 22.5 mg Injection, powder, for suspension Parenteral Injection, powder, for suspension, extended release Intramuscular 22.5 MG Suspension Parenteral 11.25 mg Injection, powder, for suspension Subcutaneous 30 mg Injection, powder, for solution Injection, powder, for solution Parenteral 3.75 MG Injection, powder, for solution Parenteral 11.25 mg Injection, powder, for suspension Subcutaneous 11.25 mg Kit Subcutaneous; Topical Injection, powder, for suspension, extended release; kit Intramuscular 22.5 mg / vial Injection, powder, for suspension, extended release; kit Intramuscular 3.75 mg / vial Powder Intramuscular 1.88 mg/1vial Powder Intramuscular 3.75 mg/1vial - Prices
Unit description Cost Unit Eligard 45 mg syringe 2959.2USD syringe Eligard 30 mg syringe 1972.8USD syringe Eligard 22.5 mg syringe 1479.6USD syringe Lupron 2-wk 1 mg/0.2 ml kit 594.37USD kit Eligard 7.5 mg syringe 493.2USD syringe Leuprolide Acetate 1 mg/0.2ml Kit 2.8ml 2-Week Kit 400.74USD box Leuprolide 2wk 1 mg/0.2 ml kit 385.33USD kit DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US6036976 No 2000-03-14 2016-12-13 US US8921326 No 2014-12-30 2031-02-05 US US7429559 No 2008-09-30 2019-01-13 US US8815801 No 2014-08-26 2022-06-28 US US5728396 No 1998-03-17 2017-01-30 US US6156331 No 2000-12-05 2017-01-30 US US6375978 No 2002-04-23 2018-12-17 US US6235712 No 2001-05-22 2017-06-13 US US6113938 No 2000-09-05 2018-07-24 US US6124261 No 2000-09-26 2017-06-13 US US6395292 No 2002-05-28 2017-01-30 US US6132420 No 2000-10-17 2017-01-30 US US5985305 No 1999-11-16 2017-01-30 US US5932547 No 1999-08-03 2017-06-13 US US6565874 No 2003-05-20 2018-10-28 US US6773714 No 2004-08-10 2018-10-28 US US6626870 No 2003-09-30 2020-03-27 US US9283282 No 2016-03-15 2018-10-28 US US9254307 No 2016-02-09 2018-10-28 US US8486455 No 2013-07-16 2018-10-28 US US8840916 No 2014-09-23 2020-11-13 US US8470359 No 2013-06-25 2023-10-15 US US9539333 No 2017-01-10 2020-11-13 US US9914802 No 2018-03-13 2020-11-13 US US10646572 No 2020-05-12 2027-01-16 US US9572857 No 2017-02-21 2027-01-16 US US9744207 No 2017-08-29 2027-01-16 US US9789064 No 2017-10-17 2020-12-15 US US9617303 No 2017-04-11 2028-03-22 US US11717555 No 2019-01-01 2039-01-01 US US11771841 No 2021-12-22 2041-12-22 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 150-155 https://www.trc-canada.com/product-detail/?L330600 pKa 9.6 http://products.sanofi.ca/en/eligard.pdf - Predicted Properties
Property Value Source Water Solubility 0.0338 mg/mL ALOGPS logP 1.04 ALOGPS logP -2.4 Chemaxon logS -4.6 ALOGPS pKa (Strongest Acidic) 9.49 Chemaxon pKa (Strongest Basic) 11.92 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 16 Chemaxon Hydrogen Donor Count 16 Chemaxon Polar Surface Area 429.04 Å2 Chemaxon Rotatable Bond Count 32 Chemaxon Refractivity 327.24 m3·mol-1 Chemaxon Polarizability 125.24 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 331.9503 predictedDeepCCS 1.0 (2019) [M+H]+ 333.611 predictedDeepCCS 1.0 (2019) [M+Na]+ 339.76785 predictedDeepCCS 1.0 (2019)
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Peptide binding
- Specific Function
- Receptor for gonadotropin releasing hormone (GnRH) that mediates the action of GnRH to stimulate the secretion of the gonadotropic hormones luteinizing hormone (LH) and follicle-stimulating hormone...
- Gene Name
- GNRHR
- Uniprot ID
- P30968
- Uniprot Name
- Gonadotropin-releasing hormone receptor
- Molecular Weight
- 37730.355 Da
References
- Castellon E, Clementi M, Hitschfeld C, Sanchez C, Benitez D, Saenz L, Contreras H, Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 2006 Apr-May;24(3):261-8. [Article]
- Borroni R, Di Blasio AM, Gaffuri B, Santorsola R, Busacca M, Vigano P, Vignali M: Expression of GnRH receptor gene in human ectopic endometrial cells and inhibition of their proliferation by leuprolide acetate. Mol Cell Endocrinol. 2000 Jan 25;159(1-2):37-43. [Article]
- Imai A, Takagi A, Horibe S, Takagi H, Tamaya T: Fas and Fas ligand system may mediate antiproliferative activity of gonadotropin-releasing hormone receptor in endometrial cancer cells. Int J Oncol. 1998 Jul;13(1):97-100. [Article]
- Murase M, Uemura T, Gao M, Inada M, Funabashi T, Hirahara F: GnRH antagonist-induced down-regulation of the mRNA expression of pituitary receptors: comparisons with GnRH agonist effects. Endocr J. 2005 Feb;52(1):131-7. [Article]
- Khurana KK, Singh SB, Tatum AH, Schulz V, Badawy SZ: Maintenance of increased Bcl-2 expression in uterine leiomyomas after GnRH agonist therapy. J Reprod Med. 1999 Jun;44(6):487-92. [Article]
- FDA Approved Drug Products: Lupaneta Pack for intramuscular and oral use [Link]
- FDA Approved Drug Products: Lupron Depot (leuprolide acetate) depot suspension, for intramuscular injection [Link]
- FDA Approved Drug Products: Lupron Depot-Ped (leuprolide acetate) depot suspension [Link]
- FDA Approved Drug Products: Fensolvi (leuprolide acetate) suspension [Link]
- FDA Approved Drug Products: ELIGARD (leuprolide acetate) for injectable suspension, for subcutaneous use [Link]
- FDA Approved Drug Products: Lupron Depot 3.75mg (leuprolide acetate) depot suspension [Link]
Drug created at June 13, 2005 13:24 / Updated at February 20, 2024 23:54